GIBSON DUNN

Gibson Dunn Advises Shareholders in Connection with Sale of Aicuris to Asahi Kasei

Firm News | February 27, 2026

Gibson Dunn advised the shareholders in connection with the sale of Aicuris Anti-infective Cures AG to Asahi Kasei, through its subsidiary Veloxis Pharmaceuticals, Inc. The acquisition price amounts to 780 million euros (approximately $920 million USD).

Gibson Dunn regularly advises shareholders and life sciences companies on complex cross-border M&A transactions in the pharmaceutical sector.

The Gibson Dunn M&A team was led by Dr. Dirk Oberbracht and Sonja Ruttmann and included Ryan Murr, Dr. Aliresa Fatemi, Simon Stöhlker, Andreas Rief, Tim Windfelder, and David Lübkemeier. Dr. Lars Petersen, Kai Gesing, and Yannick Oberacker advised on regulatory and antitrust. Sean Feller advised on tax. Dr. Peter Gumnior advised on labor law aspects.

Related People

Dirk Oberbracht

Sonja Ruttmann

Ryan A. Murr

Aliresa Fatemi

Simon Stöhlker

Andreas Rief

Tim Windfelder

David Lübkemeier

Lars Petersen

Kai Gesing

Yannick Oberacker

Sean C. Feller

Peter Gumnior

Related Capabilities

Mergers and Acquisitions

Private Equity

Private Company M&A Disputes

Life Sciences

Antitrust and Competition

Tax

Labor and Employment

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**